United States of America

US Advisory Panel Recommends Easing Limits on Popular Peptides

Is this a win for patient safety or a reckless conflict-of-interest disaster?

Published 2 days ago

US Advisory Panel Recommends Easing Limits on Popular Peptides

story

Above: The U.S. Food and Drug Administration headquarters in Silver Spring, Maryland, on Apr. 28. Image credit: Valerie Plesch/Bloomberg via Getty Images

The Spin

Pro-government narrative

The FDA panel's vote to back peptides is a win for patients who have been forced to navigate sketchy gray markets with zero oversight. Bringing these drugs under a proper prescription framework — with licensed compounding pharmacies and physician oversight — is exactly how you make experimental treatments safer, not more dangerous. In doing so, the panel has embarked on the responsible path forward.

The Wall Street Journal

Dr Jesse Morse on X

Government-critical narrative

The FDA panel's vote to recommend peptides ignores the agency's own scientists, who flagged serious safety risks and zero adequate human studies. All yes votes came from Kennedy appointees with direct financial ties to the peptide industry, making this a textbook conflict-of-interest disaster. By rubber-stamping these questionable substances, the panel has recklessly betrayed America's public health.

Public Citizen ITIF